NCT05796206View on ClinicalTrials.gov

A Clinical Study of MIL62 in Systemic Lupus Erythematosus

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

MIL62

An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.

DRUG

placebo

An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Beijing Mabworks Biotech Co., Ltd.

INDUSTRY